

## **LABELLING**

## **PARTICULARS TO APPEAR ON THE IMMEDIATE AND OUTER PACKAGING**

### **Bottle / Carton label**

#### **1. Name of the medicinal product**

[HA729 trade name]\* Dolutegravir/lamivudine/tenofovir disoproxil fumarate  
50 mg/300 mg/300 mg tablets  
Dolutegravir (as sodium)/lamivudine/tenofovir disoproxil fumarate

#### **2. Statement of active substance**

Each film-coated tablet contains 50 mg dolutegravir, 300 mg lamivudine and 300 mg tenofovir disoproxil fumarate.

#### **3. List of excipients**

Contains mannitol and lactose monohydrate

#### **4. Pharmaceutical form and contents**

Film-coated tablets

28 tablets

30 tablets

56 tablets

60 tablets

84 tablets

90 tablets

168 tablets

180 tablets

#### **5. Method and route of administration**

Oral use.

Read the patient information leaflet before use.

#### **6. Special warning that the medicinal product must be stored out of the reach and sight of children**

Keep this medicine out of the sight and reach of children.

#### **7. Other special warning(s), if necessary**

#### **8. Expiry date**

EXP {MM/YYYY}

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

**9. Special storage conditions**

Do not store above 30°C.

Discard 90 days after first opening. *(This is only applicable to pack size of 90)*

**10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate**

**11. Name and address of the supplier**

Strides Pharma Science Limited  
Strides House, Opp IIMB, Bilekahalli,  
Bannerghatta Road, Bangalore  
Karnataka - 560 076,  
India

**12. WHO Reference Number (Prequalification Programme)**

HA729

**13. Manufacturer's batch number**

<Batch> <Lot> {number}

**14. (Advice on) General classification for supply**

Medicinal product subject to medical prescription.

**15. Instructions on use**